Biocomposites Welcomes Novo Holdings as Investor; TA Associates Reinvests
Deal News | Mar 03, 2025 | TA Associates
Novo Holdings and TA Associates have announced a significant investment partnership involving Biocomposites, a leading medical devices company headquartered in Keele, UK. The transaction marks the culmination of TA Associates' investment since 2017 and introduces Novo Holdings as a new investor, resulting in shared control between the two firms. Biocomposites, which specializes in infection management solutions using advanced calcium compounds and specialty polymers, has made substantial strides in growth, revenue, and geographical reach. Partnering with Novo Holdings, known for their strong presence in the life sciences sector, is expected to propel Biocomposites further, enhancing product innovation and expanding its international footprint. The investment reflects both firms' commitment to advancing infection management technology that improves patient care in over 100 countries. The financial terms of the deal remain undisclosed, with Jefferies International Limited acting as the exclusive financial advisor and legal counsel provided by Goodwin Procter LLP, Kirkland & Ellis International LLP, and Linklaters LLP.
Sectors
- Medical Devices
- Private Equity
- Healthcare
Geography
- United Kingdom – Biocomposites is headquartered in Keele, UK, and plays a central role in the investment discussion.
- Denmark – Novo Holdings, one of the investors in Biocomposites, is based in Denmark.
Industry
- Medical Devices – Biocomposites operates within the medical devices sector, focusing on infection management solutions for bone and soft tissue.
- Private Equity – TA Associates and Novo Holdings are private equity firms investing in companies like Biocomposites to foster growth and innovation.
- Healthcare – The investment involves advancing healthcare solutions, particularly in infection management for patients globally.
Financials
- Not Disclosed – Financial terms of the investment transaction between Novo Holdings and TA Associates were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Biocomposites | Target Company | Company | An international medical devices company specializing in infection management in bone and soft tissue. |
| TA Associates | Selling Company/Vendor | Private Equity | Private equity firm and majority shareholder in Biocomposites since 2017, now reinvesting in the company. |
| Novo Holdings | Bidding Company/Buyer | Private Equity | New investor and co-controller alongside TA Associates, focused on life sciences. |
| Michael Harris | CEO of Biocomposites | Person | Chief Executive Officer of Biocomposites, leading the company through significant growth and innovation. |
| Jefferies International Limited | Financial Advisor | Company | Served as exclusive financial advisor to TA Associates and Biocomposites for the transaction. |
| Goodwin Procter LLP | Legal Advisor | Company | Provided legal counsel to TA Associates and Biocomposites. |
| Kirkland & Ellis International LLP | Legal Advisor | Company | Acted as legal advisor to Novo Holdings. |
| Linklaters LLP | Legal Advisor | Company | Provided legal advice to Novo Holdings. |
| Alvarez & Marsal | Financial Advisor | Company | Provided financial and tax vendor due diligence for Biocomposites. |